Physician profile
Selgrys Cisneros
NPI 1598122046
$2,754.52
in general payments reported to CMS, 2019-2025
17 companies · $350 in 2025
The $350 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,716 · 2022: $195 · 2023: $228 · 2024: $265 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $823 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $822.88 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $1,410.00 | 2021 | |
| Adaptive Biotechnologies Corporation | $198.15 | 2023-2025 | Clonoseq |
| Astellas Pharma US INC | $191.41 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $190.77 | 2023-2025 | |
| Janssen Biotech, INC. | $149.76 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Otsuka America Pharmaceutical, INC. | $124.99 | 2022 | |
| Alexion Pharmaceuticals, INC. | $121.87 | 2021 | |
| Merck Sharp & Dohme LLC | $93.18 | 2023-2025 | Prevymis, Recarbrio, Zerbaxa |
| Incyte Corporation | $49.40 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.48 | 2022 | |
| Genentech USA, INC. | $34.45 | 2021-2025 | Polivy |
| Blueprint Medicines Corporation | $28.97 | 2025 | Ayvakit |
| Astrazeneca Pharmaceuticals LP | $25.23 | 2024 | |
| Alkermes, INC. | $24.59 | 2024 | Lybalvi |
| Pfizer INC. | $23.09 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.52 | 2024 | |
| Janssen Scientific Affairs, LLC | $19.66 | 2024 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Selgrys Cisneros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.